Type 2 Diabetes Mellitus
Conditions
Brief summary
This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose and multiple-dose of DBPR108 tablets in Type 2 Diabetes Mellitus Patients.
Detailed description
This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, single-dose and multiple-dose of DBPR108 tablets in Chinese Type 2 Diabetes Mellitus Patients. The 30 eligible patients will be randomized to receive 50 mg, 100 mg, or 200 mg DBPR108 tablets.
Interventions
DRUGDBPR108 tablets
DBPR108 tablets, oral, once daily on Day 1 and Day 3-9 for a total of 8 doses.
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who meet the World Health Organization (WHO) (1999) criteria for the diagnosis and classification criteria for type 2 diabetes mellitus; 2. 18 ≤ age ≤ 75 years old, male or female; 3. Body mass index (BMI) within the range of 19-35 kg/m\^2 (inclusive), BMI = weight (kg) / height\^2 (m\^2); 4. 7.0% ≤Hemoglobin A1c (HbA1c) ≤ 9.5%; 5. Patients who voluntarily participate in the study and sign the informed consent form; 6. Patients who agree to use contraception from the signing of the informed consent form until 1 month after the end of the last medication.
Exclusion criteria
1. Fasting plasma glucose (FPG) \> 13.9 mmol/L; 2. The investigator determines that the patients need to use insulin therapy; 3. Patients with acute or serious complications of diabetes (including diabetic ketoacidosis, hyperosmotic nonketotic diabetic coma, lactic acidosis and hypoglycemia coma); 4. History of severe hypoglycemia (hypoglycemia with severe cognitive impairment and requiring other measures to help recover); 5. History of acute or chronic pancreatitis, or related diseases that are most common cause of acute pancreatitis (such as recurrent cholelithiasis, etc.); 6. History of allergy to DPP-4 inhibitors or the investigator determines that the patients may be allergic to investigational drug; 7. Patients with untreated hyperthyroidism and other diseases, which may affect blood glucose; 8. Patients who have used other hypoglycemic drugs within 14 days before the first dose; or patients who are not suitable for this study as determined by the investigator due to taking other hypoglycemic drugs; 9. Patients with inflammatory bowel disease, partial intestinal obstruction or chronic bowel disease related to obvious digestive and absorption disorders; 10. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \> 3 \* upper limit of normal (ULN), or total bilirubin \> 1.5 \*ULN; 11. Abnormal renal function: serum creatinine\>1.5 \* ULN; or eGFR\< 45 mL/min/1.73m\^2; 12. White blood cells (WBC) \< 3.0 \*10\^9/L and neutrophil count of peripheral blood \< 1.5 \* 10\^9/L; hemoglobin \< 100 g / L; triglyceride \> 5.7 mmol/L; 13. Patients who have the second or third degree atrioventricular block, long Q-T syndrome, or QTc\>500 ms without cardiac pacemaker; 14. Patients with any one of HBsAg, hepatitis C antibody, anti-HIV antibody and antibody of treponema pallidum positive; 15. Female patients of childbearing age with pregnant test positive or lactating women; 16. History of alcohol or drug abuse within 3 months before screening, alcohol abuse is average alcohol intake more than 14 units alcohol (1 unit=12 ounces or 360 mL of beer,1.5 ounces or 45 mL spirits with 40% alc/vol, 5 ounces or 150 mL grape wine); or intake any other products containing alcohol within 2 days before the first administration of investigational product; 17. Patients who smoke more than 5 cigarettes per day within 3 months prior to screening; 18. Patients with consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) within 2 days before the first administration in treatment period , or patients who have strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, etc; 19. Participation in other clinical trials or administration of any other investigational drugs or devices within 3 months before screening; 20. Patients with the following diseases: 1. Serious dysrhythmias, obvious left ventricular dysfunction, New York Heart Association (NYHA) functional class III or IV; 2. History of unstable angina pectoris, myocardial infarction, or other high-risk coronary artery diseases; 3. Uncontrolled hypertension, systolic pressure ≥160 mmHg or diastolic pressure ≥100 mmHg; 4. History of cancer , organ transplantation; 5. History of epilepsy, psychosis, severe depression, etc. 21. Not suitable for this study as determined by the investigator due to other reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in active glucagon-like peptide1 concentration | Day 1-Day 11 | Change from baseline in active glucagon-like peptide1 concentration will be assessed after single-dose and multiple-dose administration |
| Change from baseline in dipeptidyl peptidase-IV inhibition rate | Day 1-Day 11 | Change from baseline in dipeptidyl peptidase-IV inhibition rate will be assessed after single-dose and multiple-dose administration |
| Half-life(t1/2) of DBPR108 tablets | Day 1-Day 11 | T1/2 of DBPR108 tablets will be assessed after single-dose and multiple-dose administration |
| Apparent volume of Distribution(Vz/F)of DBPR108 tablets | Day 1-Day 11 | Vz/F of DBPR108 tablets will be assessed after single-dose and multiple-dose administration |
| CL/F of DBPR108 tablets | Day 1-Day 11 | Apparent clearance(CL/F) of DBPR108 tablets will be assessed single-dose and multiple-dose administration |
| Peak plasma concentration (Cmax) of DBPR108 tablets | Day 1-Day 11 | Cmax of DBPR108 tablets will be assessed after single-dose and multiple-dose administration |
| Area under the plasma concentration versus time curve (AUC) of DBPR108 tablets in plasma | Day 1-Day 11 | AUC of DBPR108 tablets will be assessed after single-dose and multiple-dose administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The number of patients with adverse events | Throughout the study period, with an average of 1 months | The number of patients with adverse events as a measure of safety and tolerability. |
| Clinically significant changes from baseline in 12-lead electrocardiogram (ECG) examination will be recorded as AEs at each visit time point | Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11). | ECG monitoring includes P-R, QT and QTc intervals in ms. |
| Clinically significant changes from baseline in vital signs examination will be recorded as AEs at each visit time point. | Throughout the study period, with an average of 1 months | Vital signs monitoring includes respiratory rate and pulse in times per minute |
| Clinically significant changes from baseline in physical examination will be recorded as AEs at each visit time point. | Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11). | Physical examination includes mucocutaneous, lymphonodus, head and neck,chest, abdomen, spinal column, musculoskeletal, nervous system |
| Clinically significant changes from baseline in routine blood test will be recorded as AEs at each visit time point. | Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11) | Routine blood test includes white blood cell count, platelet, neutrophilic granulocyte count, lymphocyte count and monocyte count in 10\^9 /L. |
| Clinically significant changes from baseline in blood biochemistry test will be recorded as AEs at each visit time point.recorded as AEs at each visit time point. | Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11) | Blood biochemistry test includes total protein, albumin and albumin in g/L. |
| Clinically significant changes from baseline in routine urine test will be recorded as AEs at each visit time point. | Within screening period (Day-21 to Day-15), baseline period (Day-7 to Day-1), and before discharge (Day11) | Routine urine test includes the count of leukocyte, and red blood cell in high-power field. |
Countries
China
Outcome results
None listed